Literature DB >> 9792220

Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans.

S Sasaki1, S Koumi, R Sato, M Murata, K Nagasawa, E Sakurai, N Hikichi, H Hayakawa.   

Abstract

Buccal absorption has an advantage when compared with other administration routes because of its rapid onset of action. We examined the pharmacokinetics of buccal-absorbed propafenone in healthy humans. 1. After a single oral administration of 150 mg of propafenone, the average peak concentration of propafenone was 27.9+/-2.5 ng/ml, and that of 5-hydroxypropafenone was 61.7+/-6.6 ng/ml (n=5). The times to reach peak serum concentrations of propafenone and 5-hydroxypropafenone were 1.8+/-0.1 hr and 1.5+/-0.2 hr, respectively. 2. After a buccal absorption of 150 mg of propafenone, the time to reach peak serum concentration of propafenone was 16.9+/-2.3 min (n=8). The average peak concentration of propafenone was 30.4+/-1.4 ng/ml (n=8), and the concentrations of 5-hydroxypropafenone were below the detection limit in all subjects. The rapid upstroke of serum concentrations of propafenone by buccal administration may cause rapid onset of pharmacological conversion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792220     DOI: 10.1016/s0306-3623(98)00045-7

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  4 in total

1.  Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine.

Authors:  Jeremy A Bartlett; Kees van der Voort Maarschalk
Journal:  AAPS PharmSciTech       Date:  2012-08-31       Impact factor: 3.246

Review 2.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Extemporaneous suspension of propafenone: attending lack of pediatric formulations in Mexico.

Authors:  Hugo Juárez Olguín; Carmen Flores Pérez; Blanca Ramírez Mendiola; Rafael Coria Jiménez; Eunice Sandoval Ramírez; Janett Flores Pérez
Journal:  Pediatr Cardiol       Date:  2008-06-28       Impact factor: 1.655

4.  Ambroxol Lozenge Bioavailability : Part II - Analysis of Additional Systemic AvailabilityPart I of this article was published in Clin Drug Invest 2003; 23 (4): 273-80.

Authors:  Damrongsak Faroongsarng; Malee Rojpibulstit; Srirat Kasiwong; Narubodee Phadoongsombat
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.